Preclinical studies have shown that IL-6/STAT3 signaling contributes to sorafenib resistance in HCC cell lines, and blockage of IL-6 increases cytotoxicity of sorafenib (Niu et al. 2018; Lai et al. 2019; Li et al. 2020). The gene discussed is IL6; the disease is hepatocellular carcinoma.